uniQure BV (NASDAQ:QURE) is a biotechnology company focused on developing gene therapies. These therapies aim to treat genetic disorders by delivering functional copies of genes to patients. The company operates in a competitive landscape with other biotech firms like Bluebird Bio and Spark Therapeutics. On March 2, 2026, RBC Capital downgraded QURE from "Outperform" to "Sector Perform," with the stock priced at $9.94, as reported by StreetInsider.
Despite the downgrade, uniQure's recent financial performance shows some positive signs. The company reported a quarterly loss of $0.56 per share, which was better than the Zacks Consensus Estimate of a $0.93 loss. This represents an earnings surprise of approximately 39.91%. Compared to the previous year's loss of $1.50 per share, this is a notable improvement.
However, uniQure's revenue performance has been less impressive. The company reported revenues of $5.57 million for the quarter ending December 2025, missing the Zacks Consensus Estimate by 21.2%. Although this is a slight increase from the $5.22 million reported a year ago, uniQure has consistently failed to meet consensus revenue estimates over the past four quarters.
The stock price for QURE is currently $10.55, reflecting a significant decrease of 32.50% from its previous high. The stock has fluctuated between $8.96 and $10.58 today, with a 52-week high of $71.50 and a low of $7.76. The company's market capitalization is approximately $649.9 million, with a trading volume of 13,733,434 shares on the NASDAQ exchange.
